Trodelvy (sacituzumab govitecan-hziy) is a brand-name drug prescribed for certain breast cancers. It’s given as an intravenous (IV) infusion by a healthcare professional. The dosage can vary ...

In Trodelvy’s FDA-approved indication of metastatic triple-negative breast cancer (TNBC), the anti-TROP-2 drug cut the risk of disease progression by 59% over chemotherapy in patients who had ...

Is Trodelvy's benefit clinically meaningful? When Gilead said in March that the study had hit its primary endpoint of improving progression-free survival (PFS), the company itself gave investors ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a confirmatory trial failed to meet its main objective ...

“Trodelvy has the potential to become a cornerstone treatment in metastatic urothelial cancer, and we are excited about the expected results from the ongoing Phase 3 TROPiCS-04 study that may ...

Trodelvy is currently approved in more than 50 countries for second-line or later mTNBC patients and in several countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer.

Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Trodelvy is the first and only approved Trop-2-directed antibody-drug conjugate (ADC) that has demonstrated meaningful survival advantages in two different types of metastatic breast cancers ...

Moreover, treatment with Trodelvy was associated with a median overall survival (time from treatment assignment and all-cause death) of 11.8 months compared to 6.9 months for those who received ...

Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months vs 7.8 months when Keytruda was given in combination with chemotherapy.